Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 1305 · Agility in Manufacturing Preparedness Act of 2025 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 247d–7e Biomedical Advanced Research and Development Authority

+1 −1Shown
More for 42 U.S.C. § 247d–7e
Read § 247d–7eOnly this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    in the second sentence, in the matter preceding clause (i), by inserting , manufacturing technologies, platforms, after countermeasures; and

  2. Carried out:

    by inserting after the first sentence the following: Such strategic coordination may include collaborating with the network of Manufacturing USA institutes established under section 34 of the National Institute of Standards and Technology Act in biomanufacturing missions to develop, demonstrate, and deploy technologies and response capabilities to improve public health and medical preparedness..

§ 247d–7e(c)(4)Duties(E)–(F)

Start of § 247d–7e to (c)(4)(E)(viii) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(E)(ix)(ix) Sunset(ix) Sunset
This subparagraph shall have no force or effect after September 30, 2028.This subparagraph shall have no force or effect after September 30, 2028.
(F)(F) Strategic initiatives(F) Strategic initiatives
The Secretary, acting through the Director of BARDA, may implement strategic initiatives, including by building on existing programs and by awarding contracts, grants, and cooperative agreements, or entering into other transactions, to support innovative candidate products in preclinical and clinical development that address priority, naturally occurring and man-made threats that, as determined by the Secretary, pose a significant level of risk to national security based on the characteristics of a chemical, biological, radiological or nuclear threat, or existing capabilities to respond to such a threat (including medical response and treatment capabilities and manufacturing infrastructure). Such initiatives shall accelerate and support the advanced research, development, and procurement of countermeasures and products, as applicable, to address areas including—The Secretary, acting through the Director of BARDA, may implement strategic initiatives, including by building on existing programs and by awarding contracts, grants, and cooperative agreements, or entering into other transactions, to support innovative candidate products in preclinical and clinical development that address priority, naturally occurring and man-made threats that, as determined by the Secretary, pose a significant level of risk to national security based on the characteristics of a chemical, biological, radiological or nuclear threat, or existing capabilities to respond to such a threat (including medical response and treatment capabilities and manufacturing infrastructure). Such [inserted: strategic coordination may include collaborating with the network of Manufacturing USA institutes established under section 34 of the National Institute of Standards and Technology Act in biomanufacturing missions to develop, demonstrate, and deploy technologies and response capabilities to improve public health and medical preparedness. Such ]initiatives shall accelerate and support the advanced research, development, and procurement of countermeasures[inserted: ,] [inserted: manufacturing technologies, platforms, ]and products, as applicable, to address areas including—
(F)(i)(i) (i)
chemical, biological, radiological, or nuclear threats, including emerging infectious diseases, for which insufficient approved, licensed, or authorized countermeasures exist, or for which such threat, or the result of an exposure to such threat, may become resistant to countermeasures or existing countermeasures may be rendered ineffective;chemical, biological, radiological, or nuclear threats, including emerging infectious diseases, for which insufficient approved, licensed, or authorized countermeasures exist, or for which such threat, or the result of an exposure to such threat, may become resistant to countermeasures or existing countermeasures may be rendered ineffective;
(F)(ii)(ii) (ii)
threats that consistently exist or continually circulate and have a significant potential to become a pandemic, such as pandemic influenza, which may include the advanced research and development, manufacturing, and appropriate stockpiling of qualified pandemic or epidemic products, and products, technologies, or processes to support the advanced research and development of such countermeasures (including multiuse platform technologies for diagnostics, vaccines, and therapeutics; virus seeds; clinical trial lots; novel virus strains; and antigen and adjuvant material); andthreats that consistently exist or continually circulate and have a significant potential to become a pandemic, such as pandemic influenza, which may include the advanced research and development, manufacturing, and appropriate stockpiling of qualified pandemic or epidemic products, and products, technologies, or processes to support the advanced research and development of such countermeasures (including multiuse platform technologies for diagnostics, vaccines, and therapeutics; virus seeds; clinical trial lots; novel virus strains; and antigen and adjuvant material); and

Rest of § 247d–7e unchanged

Step through the changes